On January 30, the FDA approved Avtozma (tocilizumab-anoh), which was formerly known as CT-P47 by Celltrion. Celltrion will market Avtozma as both intravenous and subcutaneous formulations, in the same dosages as the reference product Actemra. Avtozma received approval for the following indications: Actemra has only one indication that Avtozma does not: cytokine-release syndrome related to … Continue reading Celltrion’s Avtozma Approved by the FDA: Now There Are Three